The anticancer mechanisms of sorafenib and 5-MTP have been demonstrated to target the same molecule, the signal transducer and activator of transcription 3 (STAT3) [25, 26], which plays a crucial role in tumor cell proliferation and survival [27]. This evidence concerns the gene STAT3 and neoplasm.